Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis

Megan Cully1, Han You, Arnold J Levine

  • 1The Campbell Family Institute for Breast Cancer Research, University Health Network, University of Toronto, Toronto, Ontario M5G 2C1, Canada.

Nature Reviews. Cancer
|February 3, 2006
PubMed

Insights

Phosphatase with tensin homology (PTEN) regulates cell survival by inhibiting the phosphatidylinositol 3-kinase (PI3K) pathway. Deregulation of this critical network, through mutations or crosstalk with other pathways, contributes to cancer development.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Signaling

Background:

  • The tumor suppressor phosphatase with tensin homology (PTEN) is a key negative regulator of the phosphatidylinositol 3-kinase (PI3K) pathway.
  • While PTEN mutations are common in cancer, PI3K-PTEN network deregulation also occurs via other mechanisms.
  • Crosstalk between PI3K and other oncogenic pathways (e.g., Ras, p53, TOR, DJ1) contributes to tumor development.

Purpose of the Study:

  • To elucidate how the PI3K pathway integrates signals from diverse sources.
  • To explore the therapeutic potential of targeting the PI3K pathway in cancer treatment.

Main Methods:

  • This study involves a review and analysis of existing research on the PI3K-PTEN signaling network.
  • Focus on understanding signal integration and crosstalk mechanisms.

Main Results:

  • The PI3K pathway is a central hub integrating signals from multiple oncogenic pathways.
  • PTEN loss or inactivation is a critical event leading to uncontrolled cell survival and proliferation.
  • Interactions with Ras, p53, TOR, and DJ1 pathways highlight the complexity of PI3K network deregulation.

Conclusions:

  • Understanding PI3K pathway signal integration is crucial for cancer research.
  • Targeting the PI3K pathway and its regulators offers a promising strategy for rational cancer therapy design.

Related Concept Videos

Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...